ArticleHuman vaccines & immunotherapeutics2025

Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants.

Yulei He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.